DRKS00026982Enrolling By InvitationNot Applicable
Follow-up: Immunogenicity according to reactogenicity of Covid-19 vaccines - immunoreakt-II
niversity Medical Center Regensburg0 sites76 target enrollmentStarted: October 21, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Enrolling By Invitation
- Sponsor
- Enrollment
- 76
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 21 Years to 66 Years (—)
- Sex
- All
Inclusion Criteria
- •immunoreakt study participants who were included in the final analysis of the immunoreakt study
Exclusion Criteria
- •1) new history of SARS-CoV-2 infection
- •2) new immunosuppression (disease or medication-induced)
Investigators
Similar Trials
Recruiting
Phase 4
Evaluation of immunogenicity and reactogenicity of heterologous covid-19 vaccine combination ChAdOx-1S followed by BNT162b2prevention covidDRKS00025271niklinik Regensburg Abteilung für Hygiene und Infektiologie154
Not yet recruiting
Phase 4
Mixing of COVID vaccines studyCTRI/2021/08/035648Christian Medical College
Active, not recruiting
Phase 1
The 6-in-1 Vaccine StudyEUCTR2018-003451-38-GBClinical Trials and Research Governance (CTRG)240
Active, not recruiting
Not Applicable
The Study of the Immunogenity and Reactogenity of Trivalent, Purified, Inactivated Influenza Vaccine for Parenteral Administration in Adults, for the 2010-2011 Season, Produced by Cantacuzino National Institute of Research and Development for Microbiology and ImmunologyHealthy adult volunteers (2 age-groups: 18-60 years and >60 years old) are vaccinated in order to achieve protection against influenza virus infection with the vaccine containing the influenza virus strains recommended by WHO for the 2010-2011 season in the Northern Hemispherethe immunogenity and reactogenity of the vaccine are assessedEUCTR2010-023105-35-ROCantacuzino National Institute of Research and Development for Microbiology and Immunology
Completed
Not Applicable
Immunogenicity according to reactogenicity of Covid-19 vaccinesDRKS00025316niversitätsklinikum Regensburg90